Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Aura Biosciences Trading Down 0.8 %
AURA traded down $0.09 during trading hours on Monday, hitting $11.65. The company’s stock had a trading volume of 486,588 shares, compared to its average volume of 176,424. The business’s 50-day moving average price is $8.66 and its 200-day moving average price is $8.07. Aura Biosciences, Inc. has a 12 month low of $5.99 and a 12 month high of $12.38. The stock has a market cap of $577.18 million, a price-to-earnings ratio of -6.26 and a beta of 0.37.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.04. On average, analysts forecast that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.
Institutional Investors Weigh In On Aura Biosciences
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on AURA. HC Wainwright lifted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, Scotiabank boosted their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $23.00.
View Our Latest Analysis on Aura Biosciences
About Aura Biosciences
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Read More
- Five stocks we like better than Aura Biosciences
- Trading Stocks: RSI and Why it’s Useful
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.